Unveiling the roles of autophagy in innate and adaptive immunity

Beth Levine* and Vojo Deretic‡

Abstract | Cells digest portions of their interiors in a process known as autophagy to recycle nutrients, remodel and dispose of unwanted cytoplasmic constituents. This ancient pathway, conserved from yeast to humans, is now emerging as a central player in the immunological control of bacterial, parasitic and viral infections. The process of autophagy may degrade intracellular pathogens, deliver endogenous antigens to MHC-class-II-loading compartments, direct viral nucleic acids to Toll-like receptors and regulate T-cell homeostasis. This Review describes the mechanisms of autophagy and highlights recent advances relevant to the role of autophagy in innate and adaptive immunity.

Our armamentarium for fighting intracellular pathogens includes multiple facets of the innate and adaptive immune response. In the past few decades, we have witnessed an explosion in our understanding of the mechanisms underlying antigen presentation, immune recognition of infected cells, cellular sensing of pathogens, and signalling pathways that induce antimicrobial states in infected cells. Surprisingly, however, microbiologists and immunologists have long overlooked one of the greatest challenges that the immune system faces in dealing with intracellular pathogens — that is, the problem of how to dispose of a microorganism without disposing of the entire infected cell. A seemingly simple strategy to tackle this challenge is now beginning to unveil itself. Mammalian cells use an evolutionarily conserved lysosomal degradation pathway known as autophagy to selectively dispose of intracellular pathogens.

Autophagy is a fundamental cellular homeostatic process that enables cells to clean up, in a regulated manner, portions of their own cytoplasm and degrade their constituents. This primordial function is preserved in all eukaryotic organisms, from yeast to humans. During autophagy, an isolation membrane wraps around portions of the cytoplasm to form a double-membrane organelle known as the autophagosome. The engulfed cytoplasmic material in an autophagosome is degraded after fusion of the autophagosome with late endosomes or lysosomes (FIG. 1).

The autophagy pathway has many physiological roles, and is often used to remove damaged or surplus organelles. It is also used by cells to turn over long-lived proteins and other macromolecules, either to supply nutrients for essential anabolic needs under conditions of nutrient deprivation or growth factor withdrawal, or to rid cells of potentially toxic aggregate-prone proteins. The broad spectrum of autophagy functions is intricately linked to a wide range of health and disease states. For example, autophagy is involved in the control of development, tissue homeostasis and the lifespan of an organism; the suppression of tumour development; and the prevention of neurodegeneration. Aberrant regulation of autophagy has been mechanistically linked to cancer, Huntington’s disease, Parkinson’s disease, myodegeneration and cardiomyopathy (BOX 1).

Autophagy also functions in diverse aspects of immunity. Although the term autophagy means ‘to digest oneself’, it is now clear that the autophagy pathway also eliminates intracellular pathogens, including viruses, parasites and bacteria (a process sometimes referred to as xenophagy). The autophagic sequestration of viral components can also fuel MHC class II presentation of endogenous antigens and the production of type I interferons (IFNs) in response to Toll-like receptor 7 (TLR7) signalling. Furthermore, autophagy may directly affect T-cell homeostasis. More speculatively, autophagy may have a role in the prevention of autoimmunity and inflammatory disorders. Here, we provide an introduction to the molecular mechanisms of autophagy, discuss the major recent advances in autophagy and immunity, and highlight important unanswered questions in the field.
Autophagy: a lysosomal degradation pathway

There are several morphologically and functionally distinct forms of autophagy, including macroautophagy (herein referred to as autophagy), microautophagy, chaperone-mediated autophagy and others that involve the selective degradation of specific organelles (such as peroxisomes, mitochondria and the endoplasmic reticulum). During the initiation of autophagy, a damaged organelle or a portion of cytosol is sequestered in a structure known as the isolation membrane or phagophore (Fig. 1a). The phagophore then becomes enlarged during the elongation stages by the addition of new membrane — the origin of which is still unclear. The phagophore seals to form an autophagosome, an organelle that is distinguished from the conventional phagosome by the presence of a double delimiting membrane (two lipid bilayers) and intra-luminal cytoplasmic content. During maturation, autophagosomes fuse with lysosomes to form autolysosomes in which the captured material is degraded. The capture of intracellular pathogens is thought to follow a similar path (Fig. 1b), although the sequestration of microorganisms during autophagy has not been studied as extensively as that of cellular contents.

Most cells undergo some level of autophagy while adjusting their biomass, removing protein aggregates or eliminating damaged organelles (such as mitochondria). The classical signalling pathways that regulate autophagy have been reviewed extensively elsewhere21,22, whereas signals of particular relevance to immunity are discussed later. Key players in autophagy regulation are the serine/threonine kinase mammalian target of rapamy cin (mTOR; also known as FRAP1) and the class I and class III phosphoinositide 3-kinases (PI3Ks). Two well-characterized stimuli that induce autophagy are amino-acid starvation and growth-factor withdrawal2. In response to growth-factor stimulation, class I PI3Ks generate phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) on the plasma membrane by phosphorylating phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and in turn PtdIns(3,4,5)P3 activates mTOR, thereby repressing autophagy. The class III PI3K VPS34 (also known as PIK3C3) generates phosphatidylinositol-3-phosphate (PtdIns3P) by phosphorylating

**Box 1 | Autophagy in health and disease**

The autophagy pathway has numerous adaptive functions in eukaryotic organisms. In cellular starvation settings, autophagy functions to preserve cellular bioenergetics by providing metabolic substrates (obtained through bulk cytoplasmic degradation), which maintains macromolecular synthesis and ATP production. Another important function of autophagy that probably underlies its protective role against diverse pathologies is its ability to perform ‘routine housecleaning’ and also to clean-up toxic or damaged cytoplasmic constituents, a process that may have more selectivity than autophagy induced by cell starvation. This function of autophagy contributes to its protection against neurodegenerative disease; it has a basal role in preventing the abnormal accumulation of ubiquitylated protein aggregates and it specifically degrades toxic aggregate-prone mutant polyglutamine expansion proteins. The degradation of damaged mitochondria and other organelles also may underlie the anti-ageing effects and the tumour suppressor effects of autophagy, by helping to reduce genotoxic stress and to prevent DNA damage and genomic instability. In parallel to cleaning-up endogenous cellular constituents, autophagy cleans up intracellular microorganisms, thereby protecting against disease caused by intracellular pathogens. Autophagy also can selectively deliver microbial genetic material and antigens to the innate and adaptive immune systems. Some of these effects on immune regulation and bacterial clearance may explain the recently uncovered genetic linkage between autophagy genes and susceptibility to Crohn’s disease.

Given the diverse functions of autophagy in health and disease, there is now considerable interest in targeting the autophagy pathway in the treatment of different diseases, including cancer, neurodegenerative diseases, heart diseases, ageing, infectious diseases and Crohn’s disease. However, for some of these diseases, such as cancer and heart disease, there is intense debate as to whether autophagy should be turned on or turned off, with no clear-cut data to resolve the debate. For other conditions, such as ageing and neurodegenerative diseases, presently available data suggest that autophagy augmentation is likely to be beneficial. In the case of infectious diseases, it is also likely that, at least in most cases, autophagy induction will foster increased innate and adaptive immunity. Nonetheless, the possibility that certain microorganisms may fare better in the setting of increased autophagy remains.

---

Figure 1 | **Cellular events in autophagy**. The cellular events during digestion of self constituents or intracellular pathogens follow three distinct stages: initiation (formation of the phagophore), elongation (growth and closure) and maturation of a double membrane autophagosome into an autolysosome. a | Autophagy sequesters and removes cellular constituents from the cytosol, including surplus or damaged organelles from the cytosol. b | Autophagy can eliminate bacteria (free in the cytosol or inside a phagosome), viruses and protozoan parasites in a manner similar to the elimination of self constituents.
Xenophagy
The selective degradation of microorganisms (such as bacteria, fungi, parasites or viruses) through an autophagy-related mechanism.

Macroautophagy
(Also known as autophagy). The largely non-specific autophagic sequestration of cytoplasm into a double- or multiplemembrane-delimited compartment (an autophagosome) of non-lysosomal origin. Note that certain proteins, organelles and pathogens may be selectively degraded via macroautophagy.

Microautophagy
The uptake and degradation of cytoplasm by invagination of the lysosomal membrane.

Chaperone-mediated autophagy
The import and degradation of soluble cytosolic proteins by chaperone-dependent, direct translocation across the lysosomal membrane.

Small interfering RNA (siRNA)
Synthetic RNA molecules of 19–23 nucleotides that are used to ‘knockdown’ (that is, silence the expression of) a specific gene. This is known as RNA interference (RNAi) and is mediated by the sequence-specific degradation of mRNA.

Autophagy is regulated by a set of autophagy-related proteins (ATG proteins). In the absence of amino acids or in response to other stimuli, ATG1 and a complex of the class III PI3K (phosphoinositide 3-kinase) VPS34 and beclin 1 lead to the activation of downstream ATG factors that are involved in the initiation (a), elongation (b) and maturation (c) of autophagy. a] In amino-acid-rich conditions, VPS34 contributes to mTOR (mammalian target of rapamycin) activation and inhibition of ATG1 and autophagy. The sources of membrane for autophagosome initiation and elongation may include those containing the only known membrane integral ATG protein ATG9, redistributing between a resting location to autophagosomes in an ATG1- and PI3K-dependent manner. ATG9 redistribution may depend on ATG18, which binds phosphatidylinositol-3-phosphate (PtdIns3P). b] The elongation and shape of the autophagosome are controlled by two protein (and lipid) conjugation systems, similar to the ubiquitilation systems: the ATG12 and LC3 (also known as ATG8)–phosphatidylethanolamine (PE) conjugation pathways, which include E1-activating and E2-conjugating enzymes. ATG12 is initially conjugated to ATG7 (an E1-activating enzyme) and then is transferred to the E2-like conjugating enzyme ATG10. This intermediate presents ATG12 for conjugation to an ATG5 lysine residue. The ATG5–ATG12 conjugate, stabilized non-covalently by ATG16, triggers oligomerization on the outside membrane of the growing autophagosome, and enhances LC3 carboxy-terminal lipidation through the LC3 conjugation system. Upon autophagosome closure, ATG5–ATG12–ATG16 and LC3 (delipidated by ATG4) are recycled. c] LC3 associated with the lumenal membrane remains trapped in the autophagosome and is degraded during maturation into the autolysosome, which involves fusion of autophagosomes with late endosomes, including endosomal multivesicular bodies and lysosomal organelles, and dissolution of the internal membrane. VPS34 has a role in the formation of late endosomal multivesicular bodies and lysosomal organelles contributing to the maturation stages of autophagy.

Figure 2 | Molecular events in autophagy. Autophagy is regulated by a set of autophagy-related proteins (ATG proteins). In the absence of amino acids or in response to other stimuli, ATG1 and a complex of the class III PI3K (phosphoinositide 3-kinase) VPS34 and beclin 1 lead to the activation of downstream ATG factors that are involved in the initiation (a), elongation (b) and maturation (c) of autophagy. a] In amino-acid-rich conditions, VPS34 contributes to mTOR (mammalian target of rapamycin) activation and inhibition of ATG1 and autophagy. The sources of membrane for autophagosome initiation and elongation may include those containing the only known membrane integral ATG protein ATG9, redistributing between a resting location to autophagosomes in an ATG1- and PI3K-dependent manner. ATG9 redistribution may depend on ATG18, which binds phosphatidylinositol-3-phosphate (PtdIns3P). b] The elongation and shape of the autophagosome are controlled by two protein (and lipid) conjugation systems, similar to the ubiquitilation systems: the ATG12 and LC3 (also known as ATG8)–phosphatidylethanolamine (PE) conjugation pathways, which include E1-activating and E2-conjugating enzymes. ATG12 is initially conjugated to ATG7 (an E1-activating enzyme) and then is transferred to the E2-like conjugating enzyme ATG10. This intermediate presents ATG12 for conjugation to an ATG5 lysine residue. The ATG5–ATG12 conjugate, stabilized non-covalently by ATG16, triggers oligomerization on the outside membrane of the growing autophagosome, and enhances LC3 carboxy-terminal lipidation through the LC3 conjugation system. Upon autophagosome closure, ATG5–ATG12–ATG16 and LC3 (delipidated by ATG4) are recycled. c] LC3 associated with the lumenal membrane remains trapped in the autophagosome and is degraded during maturation into the autolysosome, which involves fusion of autophagosomes with late endosomes, including endosomal multivesicular bodies and lysosomal organelles, and dissolution of the internal membrane. VPS34 has a role in the formation of late endosomal multivesicular bodies and lysosomal organelles contributing to the maturation stages of autophagy.

by small interfering RNA (siRNA) is therefore an indispensable tool for selectively probing the role of autophagy in defined biological processes.

The execution of autophagy is mediated by evolutionarily conserved proteins known as the autophagy-related (ATG) proteins. The molecular mechanisms by which this group of proteins mediates autophagy has been the subject of recent reviews and is depicted schematically in Figure 2. Autophagosomal membrane formation and expansion is facilitated by two specialized protein conjugation systems (Figure 2), the ATG8 (known as LC3 in mammals) system and the ATG12 system. This results in the carboxy-terminal conjugation of LC3 to the lipid phosphatidylethanolamine (PE) and the localization of lipotylic LC3 (LC3-II; also known as ATG8-PE) to autophagic membranes. Membrane-associated LC3-II has become the most universally used marker for the detection of membranes that are undergoing autophagy. Interestingly, LC3 interacts with p62 (sequestosome-1; also known as SQSTM1), a protein that recognizes polyubiquitylated protein aggregates (that are too big...
Autophagy eliminates intracellular microorganisms.

a | Group A Streptococcus captured within an autophagosome. Image kindly provided by Tamotsu Yoshimori, Osaka University, Japan. b | Mycobacterium bovis bacillus Calmette–Guérin (BCG) present in a mycobacterial autophagosome (MAP) that is fusing with a multivesicular body (MVB). Image reproduced with permission from Cell Press. c | Herpes simplex virus type 1 (HSV-1) virion(s) in the process of being surrounded by an isolation membrane (left panel), engulfed inside an autophagosome (middle panel) or degraded inside an autolysosome (right panel). Image reproduced with permission from Landes Bioscience.

Autophagy in bacterial and parasitic defence

The first indication that intracellular bacteria may be degraded by an autophagy-like pathway emerged more than two decades ago in morphological studies of polymorphonuclear cells infected with Rickettsia conorii. However, before the discovery of the components of the autophagic machinery, this was difficult to prove. There was a lack of markers to unequivocally identify autophagosomes; it was difficult to follow the dynamic fate of intracellular bacteria; and it was difficult to determine the significance of bacterial association with autophagosomal membranes in host defence. Indeed, several studies proposed that autophagy was a ‘microorganism-friendly process’ that supported the intracellular survival of certain pathogens. However, with new tools available to label autophagosomes and to inactivate the autophagy pathway in infected cells, we now know that autophagy is an important host mechanism for the removal of intracellular bacteria and protozoans, in keeping with its primary function as a cytoplasmic clean-up process (FIG. 3). In parallel, many pathogens have evolved strategies to protect themselves against autophagy or to harness components of the autophagy pathway for their own benefit, although, in general, the molecular details of such strategies are not well defined.

One of the initial indications that autophagy may play a role in immunity against intracellular bacteria was provided by observations regarding the role of PtdIns3P in innate immunity. It was known that PtdIns3P participated in phagolysosomal biogenesis and microbial clearance upon macrophage phagocytosis of microorganisms. This link prompted investigations into a potential role of increased PtdIns3P production and, by extension, autophagy — as PtdIns3P is involved in the initiation of autophagy downstream of mTOR — in eliminating certain intracellular pathogens, such as Mycobacterium tuberculosis, that block normal phagolysosome biogenesis. Gutierrez et al. showed that the mycobacterial-imposed block in phagolysosomal maturation can be overcome by activating cellular autophagy, either through starvation or inhibition of mTOR. Nearly simultaneously, other studies determined that autophagy can capture intracellular bacteria that lyse the phagosome and escape into the cytosol (such as Shigella spp.) or extracellular bacteria that manage to invade the host cytoplasm (such as Group A Streptococcus). Other studies have confirmed these initial findings and extended the list of intracellular bacteria and parasites targeted by autophagy to include Listeria monocytogenes, Salmonella enterica, Francisella tularensis and Toxoplasma gondii.

There are some aspects of autophagy that may be particular to the control of intracellular bacteria. First, the size of autophagosomes that engulf intracellular bacteria tends to be considerably larger than ‘typical’ autophagosomes (that is, those clearing up cytoplasmic constituents), raising the possibility that these autophagosomes may have a different biogenesis than typical autophagosomes. Nevertheless, there are similarities in size between LC3-positive structures that clear large protein aggregates and the LC3-positive autophagosomes. This suggests that the formation of these large autophagosomes, if distinct from classical autophagy, is not reserved exclusively for microorganisms.

Another area of debate is whether autophagosomes can only target intracellular bacteria that reside in the cytosol or whether they can sequester pathogens that reside in membranous or intravacuolar compartments. As autophagy is designed to engulf membranous organelles, the autophagic enclosure of a pathogen within a membranous vacuole, such as a phagosome, should not represent an obstacle to autophagic elimination. This question has been answered experimentally using the parasite T. gondii. In T. gondii-infected cells, two different but equally potent pathways of autophagic elimination of the pathogen operate: one that disrupts the parasitophorous vacuole that harbours the protozoan and the other that does not require disruption of the parasitophorous vacuole. Thus, encasement of the pathogen in a vacuole does not seem to represent a physical barrier to autophagic capture and
elimination. It has been proposed that damage to the vacuolar membrane containing the organism may precede its autophagic sequestration3, but it is not yet known whether such damage or a molecular modification of the target membrane leads to autophagic uptake.

Another pertinent question is how pathogens that are free in the cytosol are recognized by the autophagic machinery. One possibility is that microbial proteins may be marked for autophagy by modifications, such as ubiquitylation, that are already known to modify bacterial products52, or by other yet to be identified molecular tags. Alternatively (or in addition), pattern-recognition receptors, such as TLRs, NOD-like receptors and RIG-I (retinoic-acid-inducible gene I)-like helicases, may recognize pathogen-associated molecular patterns (PAMPs) to stimulate autophagy. A related possibility is that exposure of certain epitopes at the surface of a microorganism may be involved in microbial targeting to autophagosomes. For example, exposure of a Shigella epitope that is normally unexposed (due to masking by another Shigella-encoded protein) leads to autophagic bacterial capture in cells infected with mutants lacking the epitope-masking protein43. Another possible signal that links microbial presence and autophagy could be the generation of reactive oxygen intermediates, as these are often associated with pathogen recognition by host cells and are also known to induce autophagy53,54. Future research into the mechanisms underlying the induction of autophagy by microorganisms and their targeting to autophagosomes is likely not only to uncover the specifics of how the autophagic machinery recognizes foreign material in the cytoplasm but also may shed light on how the autophagic machinery detects the cell’s own damaged organelles, aggregated proteins and other cytoplasmic targets for lysosomal degradation.

**Autophagy in viral defence**

The sequestration of intracellular pathogens during autophagy is not limited to bacteria and parasites. Autophagy can also capture virions that are newly engulfed by autophagosomes as they egress out of the vacuolar membrane containing the organism. Viruses may be marked for autophagy by modifications, such as ubiquitylation, that are already known to modify bacterial products52, or by other yet to be identified molecular tags. Alternatively (or in addition), pattern-recognition receptors, such as TLRs, NOD-like receptors and RIG-I (retinoic-acid-inducible gene I)-like helicases, may recognize pathogen-associated molecular patterns (PAMPs) to stimulate autophagy. A related possibility is that exposure of certain epitopes at the surface of a microorganism may be involved in microbial targeting to autophagosomes. For example, exposure of a Shigella epitope that is normally unexposed (due to masking by another Shigella-encoded protein) leads to autophagic bacterial capture in cells infected with mutants lacking the epitope-masking protein43. Another possible signal that links microbial presence and autophagy could be the generation of reactive oxygen intermediates, as these are often associated with pathogen recognition by host cells and are also known to induce autophagy53,54. Future research into the mechanisms underlying the induction of autophagy by microorganisms and their targeting to autophagosomes is likely not only to uncover the specifics of how the autophagic machinery recognizes foreign material in the cytoplasm but also may shed light on how the autophagic machinery detects the cell’s own damaged organelles, aggregated proteins and other cytoplasmic targets for lysosomal degradation.

Although there is perhaps less direct in vitro evidence for viruses, compared with bacteria, that autophagy functions in pathogen elimination, studies with viruses have provided the first in vivo evidence for a role of autophagy in immunity. In two different phylogenetic kingdoms, genetic manipulation of autophagy-related genes has been shown to have striking effects on viral diseases. In plants, RNAi-mediated silencing of several different autophagy-related genes increases local replication of tobacco mosaic virus and results in the uncontrolled spread of programmed cell death beyond infected plant cells60. In mice, enforced neuronal expression of the autophagy-associated protein beclin 1 reduces alphavirus replication and alphavirus-induced neuronal apoptosis and protects mice from lethal virus-induced encephalitis61. Together, these studies suggest that autophagy functions in antiviral immunity in vivo not only by restricting viral replication but also by restricting pathogen-induced cell death.

The mechanisms underlying these protective functions of autophagy are not yet defined. In principle, autophagy may function in the direct elimination of viruses (as shown in vitro), in the breakdown of host factors required for viral replication or the inhibition of innate immune signalling, and in the promotion of cell survival either by maintaining bioenergetics in virally infected cells or by removing toxic self or viral components. As discussed in more detail later, autophagy may also promote adaptive immunity by the endogenous presentation of certain viral antigens through the MHC class II pathway. Moreover, the role of autophagy in
innate antiviral immunity may not be confined to direct pathogen elimination. Lee et al. recently found that the autophagic machinery can deliver viral nucleic acids to endosomal TLRs in plasmacytoid dendritic cells in vitro, resulting in type I IFN production\(^2\). Perhaps autophagy has a similar role in type I IFN production during viral infections in vivo and in other cell types infected with viruses.

Another major line of evidence that autophagy is important in antiviral immunity in vivo is the recent discovery that, to be pathogenic, viruses need to successfully counter autophagy. An essential herpes simplex virus neurovirulence protein, ICP34.5, confers pathogenicity by binding to beclin 1 and by antagonizing the host autophagy response\(^2\). Although this is the first example of a viral virulence factor directly targeting the autophagic machinery to elicit disease, it seems probable that viral evasion of autophagy will prove to be a more general strategy that viruses use to evade host antiviral defence. Other viruses encode proteins that inhibit the autophagy function of beclin 1, including BCL-2-like proteins encoded by the oncogenic gammaherpesviruses\(^2\). In addition, numerous viruses inhibit the PKR (IFN-inducible double-stranded-RNA-dependent protein kinase) antiviral signalling pathway that is required for the induction of autophagy in virally infected cells or activate the autophagy-inhibitory class I PI3K–AKT–mTOR signalling pathway\(^2\). The multiplicity of mechanisms that diverse viruses have to turn off autophagy highlights a probable fundamental role for autophagy in antiviral immunity.

**Autophagy and viral recognition by plasmacytoid dendritic cells.** Recent evidence indicates that autophagy functions in delivering viral nucleic acids to the innate immune system\(^1\). A subset of receptors of the TLR family sense viral nucleic acids in the lumen of endosomes\(^8\). However, viral nucleic acids are most often released directly into the cytoplasm after fusion of a viral envelope with the endosomal membrane or penetration of cellular membranes by a viral capsid. This poses a topological challenge for the efficient detection of viral nucleic acids by endosomal TLRs. This challenge may be met, at least in part, by using the autophagic pathway for the delivery of cytoplasmic viral nucleic acids to endosomal TLRs, which would then lead to the induction of type I-IFN-dependent innate immune responses (FIG. 4). Recently, Lee et al. demonstrated that, for two different single-stranded RNA viral infections (Sendai virus and vesicular stomatitis virus), robust IFN production by mouse plasmacytoid dendritic cells required live, not UV-inactivated, virus infection, TLR7 expression and the autophagy gene Atg5 (REF. 12).

So, similar to the use of autophagy for endogenous antigen presentation in adaptive immunity (described later), autophagy may be used for the delivery of endogenous viral nucleic acids to their cognate innate immune detectors. The precise details of how the autophagy machinery senses viral RNA and targets it to endosomal TLR7 remain to be elucidated. Moreover, it is still unclear how the nucleic acids of DNA viruses, and even other RNA viruses, are targeted to endosomal TLRs in plasmacytoid dendritic cells, as viral replication is not required for type I IFN production in plasmacytoid dendritic cells infected with herpesviruses (DNA viruses) or influenza virus (an RNA virus)\(^12,45\). Another unexplored question is whether there is any molecular interplay between the autophagy pathway and type I IFN signalling mediated by cytoplasmic RNA helicases that function as receptors for cytoplasmic double-stranded RNA produced during viral infection.

**Autophagy and antigen presentation**

The role of autophagy in immunity is not limited to the direct elimination of intracellular pathogens or stimulation of type I IFN production. At least in certain contexts, autophagy promotes MHC class II presentation of cytosolic antigens\(^56,70\), thereby connecting autophagy with adaptive immunity. Brazil et al. demonstrated that the inhibition of autophagy with 3-methyladenine abrogated MHC class II presentation of endogenously synthesized C5 protein\(^46\). Nimmerjahn et al. reported that 3-methyladenine decreased MHC class II presentation of an endogenously expressed bacterial peptide\(^45\), and Dorfel et al. reported similar results using a tumour-associated antigen\(^49\). Paludan et al. showed that pharmacological and genetic inhibition of autophagy decreases efficient MHC class II presentation of an endogenously synthesized viral protein (Epstein–Barr virus nuclear antigen 1 (EBNA1))\(^79\). Together, these initial studies led to the generally accepted idea that the autophagy pathway allows the transfer of cytosolic antigens to late endosomal or lysosomal compartments (FIG. 4), in contrast to the processing of exogenous antigens captured through endocytosis or phagocytosis in antigen-presenting cells.

The autophagic delivery of cytosolic antigens to endosomes and/or lysosomes represents an attractive model for explaining why the MHC class II peptidome contains many peptides of cytosolic or nuclear origin that cannot be delivered to MHC class II compartments by the classical exogenous route. However, it is not yet clear how universal a role autophagy has in the delivery of self and foreign cytosolic and nuclear antigens. Interestingly, high levels of autophagy activity are observed in the thymic epithelial cells of newborn mice that transgenically express a fluorescently tagged autophagy marker (green fluorescent protein (GFP)–LC3)\(^3\), suggesting that autophagy may indeed enable thymic epithelial cells to present self antigens to lymphocytes during positive and negative selection. Yet, the role of autophagy in MHC class II presentation of self antigens has not yet been directly examined. Moreover, whereas EBNA1 is processed by autophagy, two other Epstein–Barr-virus-encoded nuclear antigens, EBNA2 and EBNA3C, are preferentially processed by intracellular transfer of
antigenic moieties and endocytic uptake from the culture media, indicating that autophagy may only be used for MHC class II presentation of certain endogenously produced viral antigens. A fascinating question is why, even in the same cell, some microbial antigens, but not others, gain access to the MHC class II antigen-presentation pathway by autophagy.

As some of the earlier studies that showed a role for autophagy in MHC class II presentation of endogenous antigens were performed in conditions in which autophagy was upregulated by cell starvation, another important question has been whether cytosolic antigens are delivered to MHC class II molecules by autophagy under normal conditions. Recently,
Schmid et al. observed constitutive autophagosome formation in MHC-class-II-positive cells, including B cells, dendritic cells and epithelial cells. In these cells, at least one half of all autophagosomes intersect or fuse with MHC-class-II-loading compartments. This trafficking pathway may be highly relevant for antigen presentation, as the targeting of an influenza virus matrix protein (MP) to autophagosomes by fusion with the autophagosomal protein LC3 led to a 20-fold enhancement of MHC class II presentation to MP-specific CD4+ T-cell clones. This has exciting implications for vaccine development; targeting proteins for autophagic delivery to MHC-class-II-loading compartments may be an effective means to improve T helper (T_{h1})-cell responses. However, the contribution of autophagic delivery of viral antigens to adaptive immunity during natural infections has not yet been explored.

The ‘individualized’ form of autophagy termed chaperone-mediated autophagy also has a role in endogenous MHC class II presentation. Chaperone-mediated autophagy imports individual cytosolic proteins containing specific pentapeptide recognition motifs into the lysosome via a particular isoform of lysosome-associated membrane protein 2 (LAMP2a) and an accessory chaperone, the heat-shock protein HSC70. Importantly, targeting to the chaperone-mediated autophagy pathway is intrinsic to a large fraction of self proteins, as the targeting signal (KFERQ) is present in roughly 30% of all cytosolic proteins. Although the relative contribution of autophagy and chaperone-mediated autophagy in endogenous MHC class II antigen presentation is not yet known, Zhou et al. have shown that chaperone-mediated autophagy may regulate MHC class II presentation of several cytoplasmic antigens. Overexpression of LAMP2a or HSC70 increases cytoplasmic self antigen presentation, and diminished HSC70 expression reduces MHC-class-II-restricted T-cell responses to these antigens.

Now that it is known that autophagic pathways may have a role in MHC class II presentation of endogenous antigen, many important new questions arise. How important are these pathways for adaptive immunity to intracellular pathogens? What is the relationship between autophagic elimination of intracellular pathogens and MHC class II presentation of microbial antigens? Does autophagic degradation of pathogens provide a source of antigens for loading into MHC class II compartments and/or does the autophagic machinery independently capture newly synthesized microbial peptides? How are microbial (and self) antigens targeted for autophagic delivery to MHC-class-II-loading compartments? Beyond immunity against infection, what is the broader significance of autophagic antigen processing and presentation in an MHC-class-II-dependent manner? It will be interesting to unravel the role of this pathway not only in immunity against infection, but also in cancer immunology, central and peripheral tolerance, autoimmunity and transplant rejection.

### Autophagy regulation by immune signals

The relationship between autophagy and immunity is bidirectional. Not only does autophagy, at least in certain contexts, enhance innate and adaptive immune responses, but in parallel, cytokines, receptors and ligands involved in innate and adaptive immunity enhance autophagy. Immune signalling molecules that have been shown to positively regulate autophagy in some contexts include PKR, IFNγ (and its downstream effector immunity-related GTPases), tumour-necrosis factor (TNF), and the CD40–CD40L (CD40 ligand) interaction. By contrast, autophagy is negatively regulated by the T_{h2}-type cytokines, interleukin-4 (IL-4) and IL-13, although this has been shown so far only in a non-immune cell line.

In general, there is a correlation between activation of autophagy by immune mediators and the control of infection with intracellular pathogens. The PKR signaling pathway is an important arm of the innate defence pathway against viruses and is required for virus-induced autophagy. Cell-mediated immunity can induce autophagy through CD40–CD40L stimulation and protect target cells against the vacuolar parasite T. gondii. IFNγ and TNF are crucial for protection against infection by mycobacteria and other pathogens that replicate in macrophages, and are potent inducers of autophagy in both macrophages and other cell types. It is interesting to note the contrasting roles that the T_{h1}-type cytokines IFNγ and TNF, and the T_{h2}-type cytokines IL-4 and IL-13 may have on the regulation of autophagy. Perhaps, T_{h1}-cell responses activate autophagy, thereby affording protection against intracellular microorganisms, whereas T_{h2}-cell responses dampen the autophagic response, thus, potentially explaining the negative role that the T_{h2}-cell response has in the control of intracellular pathogens.

### p47 GTPase-mediated regulation of autophagy

Recent advances have been made in identifying the molecular mechanisms that underlie the antimicrobial action of IFNγ-induced autophagy. The mouse genome contains 23 different immunity-related GTPases that are responsive to IFNγ and that have been long known to have a role in defence against a wide range of intracellular pathogens. However, until recently, the mechanisms by which these immunity-related GTPases control intracellular pathogens have remained unclear, as has the question of whether human immunity-related GTPases have a similar role in defence against intracellular pathogens. This has been partially resolved by the recent discoveries that both the mouse and human p47 GTPase family member immunity-related GTPase family, M (IRGM; also known as LRG47) and T-cell-specific GTPase (TGTTP).

Although the expression of human IRGM is not regulated by IFNγ, cells must be stimulated with this cytokine, or other physiological or pharmacological inducers of autophagy, for IRGM to exert its action. The exact mechanisms by which IRGM promotes autophagy...
are not known, but they may depend on direct or indirect interactions with organelles, regulators or effectors of the autophagic pathway. Alternatively, in view of the putative function of IRGM as a dynamin-like membrane remodelling protein, autophagy induction may be indirectly promoted by IRGM-induced changes to the parasitic vacuole membrane.

**Autophagy and T-cell homeostasis**

Autophagy has a central role in life and death decisions of numerous cell types across diverse phyla, functioning both as a pro-survival mechanism during nutrient deprivation and other forms of cell stress and as a cell-death mechanism in other contexts, such as in cells defective in apoptosis and in cells with very high levels of autophagy. Recent studies indicate that this homeostatic role of autophagy extends to T cells.

Pools of mature T cells in the periphery are subject to tight regulation that must balance naive T-cell flux following thymic selection with effector T-cell proliferation, cell death and differentiation. A role for autophagy in T-cell survival and proliferation has been shown using lethally irradiated mice repopulated with haematopoietic cells from fetal livers of Atg5<sup>−/−</sup> mice. CD4<sup>+</sup> and CD8<sup>+</sup> T cells from Atg5<sup>−/−</sup> mice fail to undergo efficient proliferation after T-cell receptor stimulation. Moreover, Atg5<sup>−/−</sup> T cells develop normally in the recipient thymus, but fail to repopulate the periphery due to overwhelming cell death. One interpretation of this finding is that T cells, on exit from the thymus, become exposed to nutritional stress owing to limitations in trophic factor support (such as IL-7) and require autophagy to sustain them during this period. At present, it is not known how autophagy affects immunological memory, but based on its role in the maintenance of other long-lived cells, such as neurons, the prediction is that autophagy may also have a role in maintaining memory T cells.

In contrast to its function as a T-cell survival process, excessive autophagy has been linked to the cell death of effector T cells under conditions that model normal homeostasis. Li et al. found that T<sub>H</sub>2 cells become more resistant to cell death induced by growth-factor withdrawal when autophagy is blocked using pharmacological or genetic methods. This cell death process may be exploited by viruses such as HIV, as the HIV envelope glycoprotein has been shown to induce autophagic cell death by binding to CXC-chemokine receptor 4 (CXCR4) in uninfected bystander CD4<sup>+</sup> T cells. However, in CD4<sup>+</sup> T cells, the natural ligand of CXCR4, CXC-chemokine ligand 12 (CCL12; also known as SDF1α), induces lymphocyte activation and homing rather than cell death, indicating divergent outcomes in T-cell physiology in response to engagement of the same cellular chemokine receptor by a viral glycoprotein versus its endogenous ligand.

Future studies are needed to determine the role of this phenomenon in CD4<sup>+</sup> T-cell depletion in patients with AIDS and to better define the factors that regulate whether autophagy has a pro-survival or pro-death role in lymphocytes. Given the extensive molecular interplay between autophagy and apoptosis, it is not surprising that autophagy might have a dual role in T-cell homeostasis, executing both life and death decisions. Furthermore, there is no reason to think that the homeostatic role of autophagy will be confined to T cells; as research in the field progresses, we are likely to witness the unfolding of crucial roles for autophagy in maintaining not only homeostasis but also proper differentiation and function of other populations of immune cells.

**Autophagy in inflammation and autoimmunity**

An unexpected link between autophagy and the removal of apoptotic cell corpses has recently been reported, which raises some intriguing possibilities about a role for autophagy in the prevention of inflammation and autoimmunity. Qu et al. found that autophagy provides apoptotic cells with signals to ensure their clearance during programmed cell death. It is well established that the rapid removal of apoptotic cell corpses is crucial for the prevention of tissue inflammation and, indeed, autophagy-deficient Atg5<sup>−/−</sup> embryos have increased inflammation in tissues that have impaired clearance of apoptotic cells. Moreover, it is now believed that defective clearance of apoptotic cells overcomes tolerance to self antigens and leads to autoimmune diseases such as systemic lupus erythematosus (SLE) and Crohn's disease.

Of great interest, a strong genetic link has recently been uncovered between autophagy and Crohn's disease, a chronic inflammatory disease of the intestine. Several recent genome-wide scans have identified a strong association between a non-synonymous single-nucleotide polymorphism (SNP) in the autophagy gene ATG16L1 (T300A variant) and susceptibility to Crohn's disease. In addition, the gene encoding the autophagy-stimulatory GTPase IRGM has been identified as a susceptibility gene for Crohn's disease. Together, these studies are suggestive of a role for autophagy dysregulation in the pathogenesis of Crohn's disease. This hypothesis will be strengthened if the ATG16L1 variant associated with Crohn's disease is found to lead to defective autophagy function.

It is not yet known how autophagy might be mechanistically linked to susceptibility to Crohn's disease. The pathogenic mechanisms of Crohn's disease are poorly understood but are speculated to involve a dysregulated immune response to commensal gut bacteria and possibly defects in mucosal barrier function or bacterial clearance. It is therefore possible that defects in autophagy lead to altered clearance of and/or altered immune responses to commensal gut bacteria. Given the possible role of autophagy in peripheral tolerance, another speculation is that, in the setting of decreased autophagy, tolerance induction might fail and produce gut-reactive immune responses. As the intestine is a site of constant epithelial-cell shedding owing to apoptosis and regeneration, defective autophagy might also contribute to the pathogenesis of this inflammatory disorder by interfering with apoptotic cell clearance. Studies in targeted mutant mice with conditional deletions or mutations of autophagy genes should help to elucidate the pathogenetic mechanisms of Crohn's disease.
Autophagy probably originated to degrade cellular constituents, recycle nutrients and maintain cellular survival during starvation. Yet perhaps, with confrontations between primitive eukaryotes such as amoeba and bacteria, this ancient lysosomal degradation pathway evolved and became exquisitely adapted to orchestrate a multipronged defence against intracellular pathogens. The autophagy pathway degrades intracellular pathogens, and delivers microbial genetic material and antigens to the necessary cellular compartments for activation of innate and adaptive immunity. In addition to its role in defence against pathogens, it also is involved in immune-cell homeostasis and potentially, in preventing inflammation and autoimmunity. The journey forward — in deciphering how autophagy executes these and, similarly, other not yet identified immune functions — will be an exciting challenge for immunologists.

Note added in proof
While this manuscript was in press a new link was reported between pattern-recognition receptors of innate immunity and stimulation of autophagy. Xu et al. found that the Gram-negative bacterial lipopolysaccharide induces autophagy in macrophages through a TLR4 signalling pathway.95

References
1. Klionsky, D. J. & Emr, S. D. Autophagy as a regulated pathway of cellular degradation. Science 290, 1717–1721 (2000).
2. Lum, J. J., DeBenedardis, R. J. & Thompson, C. B. Autophagy in metazoans: cell survival in the land of plenty. Nature Rev. Mol. Cell. Biol. 6, 459–448 (2005).
3. Levine, B. & Klionsky, D. J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6, 465–477 (2004).
4. Shintani, T. & Klionsky, D. J. Autophagy in health and disease. Annu. Rev. Pathol. 5, 165–197 (2010).
5. Levine, B. & Klionsky, D. J. Autophagy in health and disease. Annu. Rev. Biochem. 80, 321–352 (2011).
6. Schmid, D., Dengel, J., Schoor, A., Stevanovic, S. & Munz, C. Autophagy in innate and adaptive immunity against intracellular pathogens. J. Mol. Med. 84, 1–9 (2006).
7. Sato, K., Taniguchi, N. & Itoh, H. Autophagy as an immune defence mechanism. Curr. Opin. Immunol. 18, 357–362 (2006).
8. Andrade, R. M., Wessendarp, M., Gubbels, M. J., Striepen, B. & Subauste, C. S. CD60 induces macrophage anti-Toxoplasma gondii activity by triggering autophagy-dependent fusion of pathogen-containing vacuoles and lysosomes. J. Clin. Invest. 116, 2366–2377 (2006).
9. Ling, Y. M. et al. Vacuolar and plasma membrane stripping and autophagic elimination of Toxoplasma gondii in primed macrophages. J. Exp. Med. 205, 2063–2071 (2006).
10. Amano, A., Nakagawa, I. & Yoshimori, T. Autophagy in innate immunity against intracellular bacteria. J. Biochem. 140, 161–166 (2006).
11. Menendez-Benito, V. & Neelefs, J. Autophagy in MHC class II presentation: sampling from within. Immunity 26, 1–3 (2007).
12. Lee, H. K., Lund, J. M., Ramanathan, B., Mizushima, N. & Iwakawa, S. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Cell Res. 17, 1398–1403 (2007).
13. Happe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genet. 39, 207–211 (2007).
14. Roux, J. D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genet. 39, 506–604 (2007).
15. Prescott, N. J. et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBDS. Gastroenterology 132, 1655–1665 (2007).
16. The Worldwide Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 5,000 shared controls. Nature 447, 661–678 (2007).
17. Parke, M. et al. Sequence variants in the autophagy gene IRGM and mismatch repair loci contribute to Crohn's disease susceptibility. Nature Genet. 39, 850–852 (2007).
18. References 15–22 provide first genetic evidence that human autophagy genes are linked to susceptibility to inflammatory disease. They demonstrate that polymorphisms in IRGM and ATG16L1 are strongly associated with Crohn's disease.
19. Byrde, M. P., Murray, T. J. & Backer, J. M. NpL3 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280, 33076–33082 (2005).
20. Kobukuri, T. et al. Amino acids mediate mTORC1 signaling through activation of class 3 phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA 102, 16238–16243 (2005).
21. Kihara, A., Kabeya, Y., Ohsumi, Y. & Yoshimori, T. Beclin–phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2, 330–335 (2001).
22. Liang, C. et al. Autophagic and tumour suppressor activity of a novel Beclin 1-binding protein UVRAG. Nature Cell Biol. 8, 688–695 (2006).
23. Himeno, T. et al. Beclin-1 regulates autophagy and development of the nervous system. Nature 447, 1121–1125 (2007).
24. Pattingre, S. et al. Beclin 2 antagonizes autophagosome formation in yeast. J. Cell Biol. 195, 927–939 (2009).
25. Wallrath, L. S., Looit, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006).
26. Seglen, P. O. & Gordon, P. B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl Acad. Sci. USA 79, 1889–1892 (1982).
27. Klionsky, D. J. The molecular and cellular biology of autophagy. Nat. Cell Biol. 5, E146–E152 (2003).
28. Ohsumi, Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nature Rev. Mol. Cell. Biol. 2, 211–216 (2001).
55. T alloczy, Z., Virgin, H. histocompatibility complex class II molecules.
50. degradation of intracellular protein in macrophages cells.
62. that autophagy inhibition is a mechanism by which protein.
66. Orvedahl, A. of an antimicrobial effect of an autophagy gene.

References 56–57 indicate a role for components (2004).

Zhang, H. PLoS Pathog. 2, 1639–1651 (2003).

Levad, B. & Yue. J. autophagy in cell death: an innocent convict? J. Clin. Invest. 115, 2679–2688 (2005).

Yoshimori, T. Autophagy: paying Charon's toll. Cell 128, 853–866 (2007).

Expert, L. et al. Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CD4. Nature Immunol. 6, 100–109 (2005).

Maderna, J. & Godson, C. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim. Biophys. Acta 1749, 393–407 (2006).

Gaspil, U. et al. Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. 305, 161–176 (2006).

Sartor, R. S. Mechanisms of disease pathogenesis: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clin. Pract. Gastroenterol. Hepatol. 3, 590–607 (2007).

Baumgart, D. C. & Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627–1640 (2007).

Xu, Y. et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 25, 135–144 (2007).

Acknowledgements
The original work from the authors' laboratories was supported by the National Institutes of Health, USA (V.D. and B.L.) and the Ellison Medical Foundation (B.L.).

Competing interests statement
The authors declare no competing financial interests.

DATABASES
Entrez Gene: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene
AMBRIL | AGL2 | AGL4 | AGL12 | basilic | BRM | IFN | PKR | XMAP | VPS34

FURTHER INFORMATION
Beth Levine's homepage: http://www4.utsouthwestern.edu/dlab/Levine/Levine_intro.htm
Vojt Deretic's homepage: http://hsc.vcu.edu/IMC/micro/voc.html

ALL LINKS ARE ACTIVE IN THE ONLINE PDF

© 2007 Nature Publishing Group